Published on : Dec 21, 2016
Heparin, a disaccharide anticoagulant or blood thinner, is much in demand all over the world. As per the Center of Disease Control and Prevention (CDC), in the U.S. alone around 900,000 people are afflicted with deep vein thrombosis (DVT) every year. Not just that, the condition recurs in almost a third of such patients within a decade. This alarming prevalence of DVT is at the forefront of driving demand in the market for heparin in the continent. Further, in Europe almost half a million lives are claimed by coagulation disorders such as venous thromboembolism (VTE) every year. This translates as tremendous potential for the heparin market in the European region as well. Not just in Europe and North America, the increasing number of people afflicted by coagulation disorders all over the world is expected to boost the global market for heparin substantially.
New Regulatory Framework for Biosimilars to Help Market
It is expected that a new set of regulatory norms for biosimilars would likely propel the global demand for heparin products. Factors such as the extracting of animal sources for producing biosimilars will result in demand for new products shooting up, which in turn would provide tailwind to the global heparin market in the coming years.
Besides, thrust on research activities for developing marine-based heparin products is expected to flood the market with new products which will lead to further growth. In fact, big players in the market are constantly on the lookout for opportunities to merge with nimble startups to come up with new heparin products.
Alternative Anticoagulants Hurting Demand for Heparin
Nimble regional players have come up with different alternatives to heparin products such as coumarins, warfarin, and oral anticoagulant, whose soaring popularity have somewhat dampened demand for heparins. Emergence of new anticoagulants, namely rivaroxaban, dabigatran, and apixaban is also countering the growth of the global market for heparin. The increasing uptake of liquid chromatography and the reduced import of lesser-priced heparin products from China on account of strict quality control measures has also hobbled the market’s growth. Steep price of active pharmaceutical ingredients will also likely negatively impact demand by taking heparin prices higher.